639

Parkinsonism is a secondary neurodegenerative disease characterized by degeneration of dopaminergic neurons, accompanied by motor and non-motor symptoms. Primary neurodegenerative disease Alzheimer’s is a syndrome of mental retardation and memory loss. Parkinson's is one of the most common diseases in the world. It is mainly found in people over 50 years of age. According to modern statistics, about 100 million people are infected with Parkinson's disease. Of these, 40% are in North Africa and the Arab world as a whole, and about 14% are Ashkenazi Jews. This article discusses the pathophysiology of Parkinsonism and its treatment. 

  • Журнал номиRE-HEALTH
  • Нашр номи2.3-2020
  • Кўришлар сони 639
  • Ўқишлар сони 542
  • Нашр санаси 30-01-2021
  • Мақола тилиIngliz
  • Саҳифалар сони50-57
Русский

Паркинсонизм - вторичное нейродегенеративное заболевание, характеризующееся дегенерацией дофаминергических нейронов, сопровождающееся двигательными и немоторными симптомами. Первичное нейродегенеративное заболевание Альцгеймера - это синдром умственной отсталости и потери памяти. Болезнь Паркинсона - одно из самых распространенных заболеваний в мире. В основном он встречается у людей старше 50 лет. По современной статистике около 100 миллионов человек поражены болезнью Паркинсона. Из них 40% проживают в Северной Африке и арабском мире в целом, а около 14% - евреи-ашкенази. В этой статье обсуждается патофизиология паркинсонизма и его лечение. 

English

Parkinsonism is a secondary neurodegenerative disease characterized by degeneration of dopaminergic neurons, accompanied by motor and non-motor symptoms. Primary neurodegenerative disease Alzheimer’s is a syndrome of mental retardation and memory loss. Parkinson's is one of the most common diseases in the world. It is mainly found in people over 50 years of age. According to modern statistics, about 100 million people are infected with Parkinson's disease. Of these, 40% are in North Africa and the Arab world as a whole, and about 14% are Ashkenazi Jews. This article discusses the pathophysiology of Parkinsonism and its treatment. 

Ўзбек

Parkinsonizm dopaminergik neyronlarning degeneratsiyasi bilan tavsiflanadigan, ikkinchi darajali neyrodegenerativ kasallik bo'lib, motorli va motorli bo'lmagan alomatlar bilan kechadi. Birinchi darajali neyrodegenerativ kasallik bu Altsgeymer – aqliy qobiliyat va xotiradan ayiruvchi sindrom. Parkinson dunyo bo’ylab keng tarqalib borayotgam kasalliklardan biri hisoblanadi. Asosan, 50 yoshdan katta kishilarda uchraydi. Hozirgi zamon statistikasiga ko’ra 100 mlnga yaqin odam Parkinson bilan kasallangan. Ulardan 40% Shimoliy Afrikada va umuman arab dunyosida, 14% ga yaqini ashxenazi yaxudiylardir. Ushbu maqolada parkinsonizm kasalligining patofiziologiyasi va uni davolash bo'yicha so'z yuritiladi. 

№ Муаллифнинг исми Лавозими Ташкилот номи
1 Nugmanov O.. . ASMI
2 Saliyeva M.. . ASMI
3 Djalalov R.. . ASMI
4 ABDURAXIMOV A.X. . ASMI
№ Ҳавола номи
1 1. Connolly BS, Lang AE (23–30 April 2014). "Pharmacological treatment of Parkinson disease: a review". JAMA. 311 (16): 1670–83. doi:10.1001/jama.2014.3654. PMID 24756517.
2 2. The non-motor and non-dopaminergic fratures of PD. Parkinson's Disease: Non-Motor and Non-Dopaminergic Features. Olanow, C. Warren., Stocchi, Fabrizio., Lang, Anthony E. Wiley-Blackwell. 2011. ISBN 978-1405191852.
3 3. The National Collaborating Centre for Chronic Conditions, ed. (2006). "Symptomatic pharmacological therapy in Parkinson's disease". Parkinson's Disease. London: Royal College of Physicians. pp. 59–100. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010.
4 4. Zhang J, Tan LC (2016). "Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist". Current Neuropharmacology. 14 (4): 356–63. doi:10.2174/1570159X14666151208114634. PMC 4876591. PMID 26644151.
5 5. Pedrosa DJ, Timmermann L (2013). "Review: management of Parkinson's disease". Neuropsychiatric Disease and Treatment. 9: 321–40. doi:10.2147/NDT.S32302. PMC 3592512. PMID 23487540.
6 6. The National Collaborating Centre for Chronic Conditions, ed. (2006). "Palliative care in Parkinson's disease". Parkinson's Disease. London: Royal College of Physicians. pp. 147–51. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010.
7 7. Wichmann, T. (2019). Changing views of the pathophysiology of Parkinsonism. Movement Disorders. doi:10.1002/mds.27741 .
8 8. Marsili, L., Bologna, M., Kojovic, M., Berardelli, A., Espay, A. J., & Colosimo, C. (2019). Dystonia in atypical parkinsonian disorders. Parkinsonism & Related Disorders. doi:10.1016/j.parkreldis.2019.07.030.
9 9. S.M. Boesch, G.K. Wenning, G. Ransmayr, W. Poewe, Dystonia in multiple system atrophy, J. Neurol. Neurosurg. Psychiatry 72 (2002) 300–303.
10 10. W. Poewe, G.K. Wenning, The natural history of Parkinson's disease, Ann. Neurol. 44 (1998) 1–9.
Кутилмоқда